Uso de apalutamida en pacientes con cáncer de próstata hormonosensible metastásico diagnosticados mediante pruebas de imagen convencionales y de nueva generación. Datos reales de 772 pacientes

IF 1.2 4区医学 Q3 UROLOGY & NEPHROLOGY

Actas urologicas espanolas Pub Date : 2025-06-01 DOI:10.1016/j.acuro.2025.501742

M. Hassi Roman , K. Mate , P. de Pablos-RodrIguez , Á. Zamora Horcajada , A. Guijarro Cascales , Á. Sanchís Bonet , A. Vilaseca , D. Vázquez-Martul Pazos , E. Linares Espinós , J. Muñoz Rodríguez , J.M. de la Morena Gallego , J.R. Alemán , J. Gómez Rivas , L. Formisano , M.J. Juan Fita , M. Costa Planells , M. Domínguez Esteban , M. Pérez Márquez , M. García Sanz , N. García Expósito , M. Ramírez Backhaus

{"title":"Uso de apalutamida en pacientes con cáncer de próstata hormonosensible metastásico diagnosticados mediante pruebas de imagen convencionales y de nueva generación. Datos reales de 772 pacientes","authors":"M. Hassi Roman , K. Mate , P. de Pablos-RodrIguez , Á. Zamora Horcajada , A. Guijarro Cascales , Á. Sanchís Bonet , A. Vilaseca , D. Vázquez-Martul Pazos , E. Linares Espinós , J. Muñoz Rodríguez , J.M. de la Morena Gallego , J.R. Alemán , J. Gómez Rivas , L. Formisano , M.J. Juan Fita , M. Costa Planells , M. Domínguez Esteban , M. Pérez Márquez , M. García Sanz , N. García Expósito , M. Ramírez Backhaus","doi":"10.1016/j.acuro.2025.501742","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Apalutamide has shown significantly increases in radiographic progression-free survival (rPFS) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients diagnosed by conventional imaging (CI). However, there is scarce knowledge on the use of apalutamide in mHSPC population diagnosed by NGI.</div></div><div><h3>Methods</h3><div>Retrospective multicenter study of mHSPC patients treated with apalutamide from May 2018 to September 2023 registered in the Real-World Evidence APA (RWE-APA). CI and NGI group were defined, according to the diagnostic tool of metastatic disease. Primary objective was rPFS at 24 months in CI vs NGI group. Secondary objectives were OS in CI vs NGI group and rPFS in synchronic/metachronic, low volume (LV)/high volume (HV) in CI and NGI groups and risk of developing new metastasis according to the imaging technique, metastasis volume and location of the metastasis.</div></div><div><h3>Results</h3><div>772 mHSPC patients were included. 47% (359) of patients were diagnosed with CI and 53% (413) of patients with NGI. rPFS at 24 months was 80% in the CI group vs 84% in the NGI group (Hazard ratio (HR): 0.57 (0.35 – 0.92) 95% Confidence Interval [CI], p=0.023). OS at 24 months was 89.5% in the CI group and 95.8% in the NGI group (HR 0.35; 95% CI, 0.16 – 0.75, p=0.007). In the multivariable analysis, only HV was significantly associated with metastatic progression (HR 0.33 (0.18-0.59) 95% CI; p‹0.001).</div></div><div><h3>Conclusion</h3><div>mHSPC patients treated with apalutamide and NGI-diagnosed exhibited superior rPFS and OS in comparison with CI-diagnosed patients.</div></div>","PeriodicalId":7145,"journal":{"name":"Actas urologicas espanolas","volume":"49 5","pages":"Article 501742"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Actas urologicas espanolas","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0210480625000609","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Apalutamide has shown significantly increases in radiographic progression-free survival (rPFS) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients diagnosed by conventional imaging (CI). However, there is scarce knowledge on the use of apalutamide in mHSPC population diagnosed by NGI.

Methods

Retrospective multicenter study of mHSPC patients treated with apalutamide from May 2018 to September 2023 registered in the Real-World Evidence APA (RWE-APA). CI and NGI group were defined, according to the diagnostic tool of metastatic disease. Primary objective was rPFS at 24 months in CI vs NGI group. Secondary objectives were OS in CI vs NGI group and rPFS in synchronic/metachronic, low volume (LV)/high volume (HV) in CI and NGI groups and risk of developing new metastasis according to the imaging technique, metastasis volume and location of the metastasis.

Results

772 mHSPC patients were included. 47% (359) of patients were diagnosed with CI and 53% (413) of patients with NGI. rPFS at 24 months was 80% in the CI group vs 84% in the NGI group (Hazard ratio (HR): 0.57 (0.35 – 0.92) 95% Confidence Interval [CI], p = 0.023). OS at 24 months was 89.5% in the CI group and 95.8% in the NGI group (HR 0.35; 95% CI, 0.16 – 0.75, p = 0.007). In the multivariable analysis, only HV was significantly associated with metastatic progression (HR 0.33 (0.18-0.59) 95% CI; p ‹ 0.001).

Conclusion

mHSPC patients treated with apalutamide and NGI-diagnosed exhibited superior rPFS and OS in comparison with CI-diagnosed patients.

查看原文本刊更多论文

阿普鲁他胺用于通过常规和新一代成像诊断的转移性激素敏感前列腺癌患者。来自772名患者的真实数据

阿帕鲁胺显示，通过常规影像学（CI）诊断的转移性激素敏感性前列腺癌（mHSPC）患者的放射学无进展生存期（rPFS）和总生存期（OS）显著增加。然而，关于阿帕鲁胺在NGI诊断的mHSPC人群中的使用的知识很少。方法回顾性多中心研究2018年5月至2023年9月在真实世界证据APA （RWE-APA）中注册的阿帕鲁胺治疗的mHSPC患者。根据转移性疾病的诊断工具定义CI组和NGI组。主要目标是CI组与NGI组24个月时的rPFS。次要目标是CI组与NGI组的OS、CI组与NGI组的共时/超时、低容积(LV)/高容积（HV）的rPFS以及根据影像学技术、转移体积和转移部位的不同发生新转移的风险。结果纳入mHSPC患者772例。47%（359）的患者被诊断为CI， 53%（413）的患者被诊断为NGI。24个月时，CI组的rPFS为80%，而NGI组为84%（风险比（HR）： 0.57(0.35 - 0.92) 95%可信区间[CI]， p = 0.023）。24个月时CI组的OS为89.5%，NGI组的OS为95.8% (HR 0.35；95% CI, 0.16 - 0.75, p = 0.007)。在多变量分析中，只有HV与转移进展显著相关(HR 0.33 (0.18-0.59) 95% CI；p < 0.001)。结论与ci诊断的mhspc患者相比，阿帕鲁胺治疗和ngi诊断的mhspc患者表现出更好的rPFS和OS。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Actas urologicas espanolas UROLOGY & NEPHROLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

46 days

期刊介绍： Actas Urológicas Españolas is an international journal dedicated to urological diseases and renal transplant. It has been the official publication of the Spanish Urology Association since 1974 and of the American Urology Confederation since 2008. Its articles cover all aspects related to urology. Actas Urológicas Españolas, governed by the peer review system (double blinded), is published online in Spanish and English. Consequently, manuscripts may be sent in Spanish or English and bidirectional free cost translation will be provided.